Word: poulenc
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...Time Warner/deal as the largest merger ever. The most auspicious development of the past year, given Europe's historic fragmentation along national lines, is the cross-border merger. Aventis is the new, conspicuously neutral name for what used to be Germany's Hoechst and France's Rhone-Poulenc. Nor are Europeans confining their targets to the Old Continent. Even a few years ago, it would have been hard to imagine Renault buying Japanese carmaking giant Nissan or Daimler-Benz acquiring Chrysler...
...whose subsidiary Searle makes the wildly successful arthritis drug Celebrex, has been casting around for a merger partner for over a year, and now, executives say, the search is over. Monsanto will merge with Pharmacia & Upjohn, joining the ranks of other mega-merger firms like Astra-Zeneca and Rhone-Poulenc-Hoechst, to form a corporation worth about $52 billion. Why did it take so long for Monsanto to find its mate, and why was Pharmacia willing to take it on? The answers lie in Monsanto's agri-chemical division, a successful but controversial arm of the company, which...
...money that the medical center has been aggressively pursuing in recent years. Last fall Duke opened a new 10,000-sq.-ft. laboratory, a set of "clean rooms" where cell cultures can be cultivated in sterile surroundings. The $1.5 million facility was paid for by the pharmaceutical giant Rhone-Poulenc Rorer, based in Collegeville, Pa. But this particular deal is unusual in that the company has no commercial claim on any products developed through the use of the new lab. Sue Strauss is one of 18 Duke patients in Lyerly's trial, one of several vaccine tests approved...
...their own. Whenever antibiotics are used indiscriminately, mildly resistant bacteria survive and breed with one another, creating increasingly resistant germs. Pharmaceutical companies are racing to create new antibiotics that can replace vancomycin as the drug of last recourse. The leading candidate: Synercid, an experimental drug being developed by Rhone-Poulenc Rorer. Tests show that it should defeat even vancomycin-resistant staphylococci--at least until a tougher strain of bacteria evolves...
...Hurwitz, an analyst for Robertson, Stephens & Co. The list of recent mergers, as Hurwitz ticks them off, reads like a Who's Who of biotechnology: "Sandoz buys Genetics Institute. Chiron buys Viagene. Bristol Myers makes a big investment in Somatix. Merck makes a big investment in Vical. Rhone-Poulenc invests in Applied Immune Sciences and several other gene-therapy companies...